Zespy has 20+ years in the healthcare space, including 15+ years of experience working specifically with B2B2C digital health startups to help them leverage their brand to build their client base and harness behavior science and human-centered design to build and retain their patient population. She’ll lead business-to-business marketing, member marketing, and grow the CareHive brand.

Prior to joining CareHive, Linda served in leadership roles in marketing, user experience, and digital health programming for Verily (Google) Life Sciences, RedBrick Health (now Virgin Pulse) and brightpeak financial. Zespy served as a consultant to CareHive before joining the company. “I’m delighted to step into this official role, given the remarkable experience it’s been so far witnessing how CareHive is shaking up the care navigation space and, more recently, the price transparency space,” says Zespy. “Their sophisticated approach to data, engagement, and navigation adds up to real-time ROI and better care for patients.”

“Linda has demonstrated exceptional results in her career, attracting new users and changing their health and financial behaviors through relationship-building,” says Ronald Dixon, MD, CEO of CareHive. “That, combined with her deep expertise and innovative approach to fueling growth is an investment that will allow us to expand our footprint.”

About CareHive:

Every patient is unique. That’s why CareHive’s navigation platform is a personalized, digital-first experience, backed up with human support. We build relationships that drive behavior change by helping patients get the lightest doses of high-quality care for less money. Visit CareHive.com to learn more about how CareHive is using smart navigation technology to help solve some of the most challenging access, cost and quality issues in healthcare.

Contacts

Dan Moloney, Ph.D.
Chief Operating Officer
dmoloney@carehive.com
651.329.9229

Dr. Thourani is the Bernie Marcus Chairman of the Department of Cardiovascular Surgery for Piedmont Heart Institute and Piedmont Healthcare and the Marcus Heart Valve Center, strengthening egnite’s medical advisory board with his background in cardiovascular surgery and academic research. Over Thourani’s distinguished career, he has held key leadership positions as the past-president of the Southern Thoracic Surgical Association, past-president of the Heart Valve Society, past-president of the International Society of Minimally Invasive Cardiothoracic Surgery, president-elect of the 21st Century Cardiothoracic Surgical Society, past-president of the South Atlantic Cardiovascular Surgery, and the Treasurer of the Society of Thoracic Surgeons. He has authored over 740 peer-reviewed publications in major medical journals. Thourani’s leadership roles in prominent cardiovascular associations and research underscore his invaluable contributions to furthering egnite’s mission and the direction of its flagship solution, the CardioCare platform.

Nicholas Amoroso, MD, is an interventional cardiologist and director of the Medical University of South Carolina’s Adult Cardiac Catheterization Laboratory who brings expertise in structural heart and coronary artery disease to the advisory board. Amoroso is an emerging leader in the field, serving as an investigator for several landmark structural heart clinical trials and as a proctor for novel structural heart interventions. Amoroso’s prominent background in cardiology includes medical training at George Washington University as well as residency and fellowship programs at NYU and Mount Sinai Beth Israel. His involvement in novel clinical trials and contributions to leading cardiology research brings a wealth of experience to egnite’s medical advisory board.

“We are honored to welcome Vinod and Nick to egnite’s Medical Advisory Board,” said Joel Portice, president and CEO of egnite. “Their collective expertise will play a pivotal role in shaping the future of digital health for cardiovascular patients. I look forward to Vinod and Nick’s partnership as we continue to develop innovative solutions in the cardiovascular community.”

The appointment of Thourani and Amoroso to its Medical Advisory Board underscores egnite’s commitment to excellence and advancement in developing solutions to address the evolving needs of cardiovascular patients and providers.

About egnite, Inc.

egnite is a visionary digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.

egnite, egnite, Inc., CardioCare, and the spark logo are trademarks of egnite, Inc. All other trademarks are the property of their respective owners.

Contacts

Torrey Loper
egnite
torrey.loper@egnitehealth.com

ATLANTA–(BUSINESS WIRE)–myphysician360, the industry leader in developing innovative solutions for the clinical care-process partnership between local pharmacies, patients, and health plans, has announced the appointment of Alexander Poston, Jr., as its Chief Technology Officer (CTO).

Poston will lead myphysician360’s software engineering, operations, and customer support teams’ execution of the company’s technical vision and strategy, while overseeing the development and delivery of myphysician360’s novel solution for rural healthcare.

“Alex brings a proven track record of success to the role at myphysician360, and I am confident that his leadership will inspire our team members as we continue to innovate and provide game-changing solutions for the rural local community pharmacist,” said Michael Muchnicki, CEO, myphysician360.

“The delivery of healthcare to rural and medically underserved communities requires new and unique modern solutions,” Poston added. “I am excited to join a company focused on enabling exceptional care for rural communities through a combination of trusted healthcare partners and innovative technology-enabled solutions.”

Poston joins myphysician360 with more than over 25 years of entrepreneurial leadership experience and is known for expertly developing and acquiring new technological innovations, solutions, and tools to improve the delivery of healthcare for the patient and the healthcare systems. With an extensive background in the healthcare technology space, Poston has previously served as CEO of Digibyte, President and CIO of Entrada and CIO of Total eMed.

About myphysician360

myphysician360 is leading Digital Health innovation in rural America, providing a solution to improve access to care through the company’s national network of rural community pharmacies. The myphysician360 value proposition serves pharmacies, patients, and health plans by directly addressing the many challenges in rural healthcare in America. Operating in all 50 states, myphysician360’s medical group of Board-Certified Internal Medicine clinicians provides on-demand primary and urgent care 365 days a year. To learn more, visit: http://www.myphysician360.com.

Contacts

myphysician360.com
Sumedha Jani
360-209-2156
sjani@myphysician360.com

TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in chronic and acute wound care, has appointed Neil Sharma as its new Chief Commercial Officer, and Joseph Filippoli as its new Chief Information Officer, effective immediately.

Sharma is a seasoned global business leader and change agent with deep experience driving successful go-to-market strategies for corporate and startup technology-led business across the digital health ecosystem. Most recently, Sharma served as Executive Vice President at Sword Health, a trailblazer in digital physical therapy that Sharma helped scale to a $1.8B valuation. Prior to that, he held leadership positions at Accolade Health (personalized care delivery navigation and advocacy), nuVizz (hospital system logistics), and Pinn (healthcare cybersecurity). Sharma is also credited with pioneering Microsoft’s entry into mobile digital media and running the largest P&L at Samsung Mobile.

Filippoli brings over three decades of experience leading healthcare technology enterprises, driving technology innovation, operational efficiency and bottom-line profitability. Prior to Swift, Filippoli served as the founding Chief Information Officer at Tabula Rasa HealthCare (clinical pharmacy). He also formerly served as the Information Technology Health System Director at Children’s Hospital of Philadelphia. Additionally, Filippoli helped found the successful high growth startup ExcelleRx, Inc.

“It is my great pleasure to welcome these two digital health powerhouses to continue propelling Swift’s growth strategy and expansion into new markets,” said Brian Litten, CEO of Swift. “Neil and Joe both have successful track records of scaling innovative healthcare companies and driving adoption of new technologies. Together, we can continue to revolutionize wound care for the millions of patients and providers in need.”

Chronic wounds are the leading risk factor for hospitalizations, with almost 20% of the Medicare population experiencing a chronic wound at any given time. Conservative estimates for the yearly cost of wound care in the U.S. is more than $67B, which is estimated to rise to $82B by 2030 with the increased rates of chronic diseases, like diabetes, and an aging population.

“Swift is the leading clinically driven wound care imaging and documentation software solution in the market today with more than 20 peer reviewed publications, the most in its category,” said Neil Sharma, CCO of Swift Medical. “It is uniquely positioned to support clinicians who are serving this growing, high-risk population and I look forward to accelerating the company’s mission to provide high-quality patient-centric care to improve clinical and operational outcomes.”

Filippoli is currently directing Swift’s Information Technology enterprise, including overseeing Swift’s platform upgrade to optimize service, security and interoperability for current customers and the largest payers and risk-bearing providers.

“With the evolving healthcare landscape, our platform must exceed the expectations of providers across the care continuum today and tomorrow. It is my mission to deliver on that commitment,” said Joe Filippoli, CIO of Swift Medical.

About Swift Medical

Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care and approximately 20,000 nurses and doctors use our platform each month. More than 20 million wound images and 40 million assessments have been captured through the app, which has empowered healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at www.swiftmedical.com.

Contacts

Media
Kristen Abel
416-949-9159
kristen.abel@swiftmedical.com

As the company approaches commercialization, CorVista Health recognizes the importance of enhancing its Board of Directors with specialized expertise in the field of cardiovascular care. Dr. Attebery’s significant contributions in reshaping the model of cardiovascular care delivery in the USA through his innovative leadership at organizations such as the American College of Cardiology and Cardiovascular Associates of America make him a highly valued addition to the board.

“Our shareholders, along with the leadership team of CorVista Health, are thrilled to have Tim join our Board of Directors,” said Don Crawford, President, and CEO of CorVista Health. “His insights and expertise will enrich our board, and I am confident that his vast experience in healthcare and leadership will be instrumental in driving our future growth and development.”

As a member of our board, Dr. Attebery will provide further guidance and governance, drawing from his deep understanding of the cardiovascular healthcare space. His involvement will additionally support CorVista Health as it enters the next phase of growth following FDA Breakthrough Designation for their pulmonary hypertension focused device.

“I believe CorVista Health can transform the way cardiovascular disease is diagnosed, particularly in underserved geographies and populations with the greatest need,” said Dr. Attebery. “Advancements in healthcare are essential to help improve the diagnosis of cardiovascular patients especially in rural areas, and CorVista’s innovative solution has the potential to make a tremendous impact to our healthcare system.”

About CorVista® Health

CorVista Health, Inc. is applying machine learning to develop a novel cardiac diagnostic platform, CorVista® System, with the aim of transforming cardiovascular care and the patient experience. For more information, visit corvista.com CorVista Health is dedicated to addressing the FDA’s call to action for leveraging health technologies to advance health equity, as presented by FDA Commissioner, Dr. Robert Califf. Particularly, the decline in life expectancy in rural areas has been cited as key evidence of disparate health outcomes. CorVista System has the potential to enable more equitable care by providing access to immediately actionable, high-quality cardiovascular status results in low-resource settings, where access to capital-intensive equipment and the qualified specialists needed to operate them may not be available. In this way, the CorVista System is uniquely positioned to advance the quality of care in rural and low-resource settings.

About CorVista® System

CorVista System is a non-invasive point-of-care solution that is intended to synchronously collect and apply machine learning to a patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting or exercise. Within minutes of the test, the CorVista® Analysis is available in a secure web portal to aid physicians in rapidly diagnosing and treating patients with suspected cardiovascular disease, answering important clinical questions to guide better treatment decisions. CorVista System is an investigational device limited by federal law to investigational use. CorVista System is not available for commercial distribution.

Contacts

Chris Bing Ernst
415.710.9445
cernst@corvista.com

SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the appointment of Deborah Castillo, PhD, as Vice President of Regulatory Affairs.

Castillo is an experienced biomedical engineer with extensive knowledge of Food and Drug Administration (FDA), EU, and Health Canada regulations. She has significant expertise in cardiovascular diseases and neuroscience, and medical devices that support these functions. Prior to joining HeartBeam, Deborah was Director of Regulatory Affairs Neuromodulation, at LivaNova, a global medical device company creating neuromodulation devices and cardiopulmonary products, developing and implementing the regulatory strategies for various Class III devices. From 2012 to 2018 Deborah held various roles at the FDA including Acting Branch Chief, Senior Lead Reviewer, and Lead Scientific Reviewer overseeing and conducting various file reviews of program-specific projects including original 510(k)s, PMAs, IDEs, HDEs, De Novo, Pre-cert and Digital Health submissions encompassing a wide-range of cardiovascular and neurological medical devices. She holds a PhD in Biomedical Engineering from The Johns Hopkins University and a BS in Biomedical Engineering from the University of Miami.

In her new role, Castillo will be responsible for leading HeartBeam’s regulatory affairs function and overseeing the company’s interactions with regulatory agencies worldwide. She will also support the company’s clinical development and commercialization efforts for its novel HeartBeam AIMIGo Platform Technology, which is currently under review by the FDA.

“We are privileged to have Deborah join HeartBeam as a strong addition to our senior leadership team,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam. “She is a seasoned regulatory leader with a proven track record of bringing novel medical technologies to market. Her expertise will be invaluable in leading our regulatory strategy and execution.”

Castillo added, “I am honored and excited to join HeartBeam at this pivotal time. I have been impressed by the Company’s vision, technology, and team. I look forward to working with them to achieve our regulatory milestones and deliver on our promise of providing fast and accurate at-home use heart attack detection to patients around the world, bringing lifesaving diagnostic capabilities directly to patients.”

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.

Forward-Looking Statements

All statements in this release that are not based on historical fact are “forward-looking statements.” While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Contacts

Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us

Media Contact:
media@heartbeam.com

Tomer Stavitsky joins as VP of Corporate Development to lead M&A strategy focused on Artificial Intelligence (AI)

BOSTON–(BUSINESS WIRE)–Allurion Technologies, Inc. (“Allurion”), a company dedicated to ending obesity, is pleased to announce two major additions to the team. Douglas Hudson has been appointed to the Board of Directors of Allurion Technologies Holdings, Inc., effective as of the anticipated consummation of the proposed business combination (the “Business Combination”) between Allurion and Compute Health Acquisition Corp. (“Compute Health”) (NYSE: CPUH), and Tomer Stavitsky has joined as Allurion’s new Vice President of Corporate Development.

“We are incredibly excited to welcome both Doug and Tomer to Allurion,” says Dr. Shantanu Gaur, Allurion Founder and CEO. “Doug is an exceptional entrepreneur with deep experience in the consumerization of healthcare and digital products as both an operator and board member. Tomer brings a wealth of experience in healthcare M&A, partnerships and investments, and joins Allurion as we accelerate the expansion of our weight loss AI platform.”

Most recently, Mr. Hudson founded Tend where he has successfully leveraged his past experiences to reimagine the dental industry with a hospitality mindset. Previously, Mr. Hudson founded and led a range of successful consumer-facing ventures. He served as the founding CEO of SmileDirectClub and Chairman and CEO of DiabetesCareClub, CPAPCareClub and HearingPlanet, the latter of which became the largest online hearing aid distributor in the U.S. during his tenure.

“I am thrilled to join Allurion at a pivotal moment as it goes public and expands its reach to consumers all over the world,” says Mr. Hudson. “I am looking forward to working with my fellow board members and the company’s management to set a new standard for a best-in-class weight loss experience.”

As Allurion’s new Vice President of Corporate Development, Mr. Stavitsky will be focused on M&A and partnership strategy, particularly in AI and digital health. Previously, Mr. Stavitsky led M&A at Ginkgo Bioworks, and Corporate Development for the Digital & Data Business Unit at Intuitive Surgical. At Intuitive Surgical, Mr. Stavitsky evaluated hundreds of deals spanning AI and machine learning, digital health, telehealth and data analytics, and executed several key deals, including the acquisition of Orpheus Medical, which led to the establishment of Intuitive Surgical’s AI development center in Israel.

Allurion has previously announced that it is going public pursuant to the Business Combination with Compute Health and is expected to be listed on the New York Stock Exchange under the ticker symbol “ALUR” following the completion of the Business Combination.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform, and the Allurion Connected Scale and Health Tracker devices. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com.

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

About Compute Health

Compute Health (NYSE: CPUH) is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Compute Health is led by the management team of Omar Ishrak, Jean Nehmé and Joshua Fink. Compute Health’s strategy is to focus on healthcare businesses that are already leveraging or have the potential to leverage computational power, with an emphasis on companies in the medical device space, including imaging and robotics.

For more information about Compute Health please visit www.compute-health.com.

Important Information About the Proposed Transaction and Where to Find It

This press release relates to the Business Combination among Allurion, Compute Health and Allurion Technologies Holdings, Inc. “Pubco”. Pubco has filed a Registration Statement on Form S-4 with the Securities and Exchange Commission (the “SEC”), which includes a document that serves as a proxy statement and prospectus of Compute Health and Pubco (the “proxy statement/prospectus”) and a full description of the terms of the Business Combination. The Registration Statement has been declared effective by the SEC and the proxy statement/prospectus has been mailed to Compute Health’s stockholders and warrantholders of record as of the close of business on July 3, 2023, the record date established for voting at the Compute Health Special Meeting and Warrant Holder Meeting relating to the Business Combination. Compute Health and Pubco may also file other documents regarding the Business Combination with the SEC. This press release does not contain all of the information that should be considered concerning the Business Combination and is not intended to form the basis of any investment decision or any other decision in respect of the Business Combination. Compute Health’s stockholders, warrantholders and other interested persons are advised to read the Registration Statement and proxy statement/prospectus and any amendments or supplements thereto, and all other relevant documents filed or that will be filed in connection with the Business Combination, as these materials contain (or will contain) important information about Allurion, Compute Health, Pubco and the Business Combination. The Registration Statement and the proxy statement/prospectus and other documents that are filed with the SEC may be obtained without charge at the SEC’s website at www.sec.gov, or by directing a written request to Compute Health, 1100 N Market Street 4^th Floor, Wilmington, DE 19890.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED IN THIS PRESS RELEASE OR PASSED UPON THE MERITS OR FAIRNESS OF THE BUSINESS COMBINATION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PRESS RELEASE. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Participants in the Solicitation

Compute Health, Allurion, Pubco, certain stockholders of Compute Health, and certain of Compute Health’s, Allurion’s and Pubco’s respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from the stockholders and warrantholders of Compute Health with respect to the Business Combination. A list of the names of such persons and information regarding their interests in the Business Combination is contained in the Registration Statement and proxy statement/prospectus. Stockholders, warrantholders, potential investors and other interested persons should read the Registration Statement and proxy statement/prospectus carefully before making any voting or investment decisions. Free copies of these documents may be obtained from the sources indicated above.

Forward-looking Statements

This press release contains certain “forward-looking statements” within the meaning of the federal U.S. securities laws with respect to Compute Health, Allurion, Pubco and the Business Combination among them, the benefits of the Business Combination, the amount of cash the Business Combination will provide Pubco, the anticipated timing of the Business Combination, the services and markets of Allurion, the expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities, future plans and intentions, results, level of activities, performance, goals or achievements or other future events. These forward-looking statements generally are identified by words such as “anticipate,” “believe,” “expect,” “may,” “could,” “will,” “potential,” “intend,” “estimate,” “should,” “plan,” “predict,” or the negative or other variations of such statements. They reflect the current beliefs and assumptions of Compute Health’s management and Allurion’s management and are based on the information currently available to Compute Health’s management and Allurion’s management. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: (i) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of Compute Health’s securities; (ii) the risk that the Business Combination may not be completed by Compute Health’s business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Compute Health; (iii) the failure to satisfy the conditions to the consummation of the Business Combination, including, but not limited to, the approval of the business combination agreement by the stockholders of Compute Health and the stockholders of Allurion, the satisfaction of the minimum cash amount and the receipt of certain governmental and regulatory approvals; (iv) changes to the proposed structure of the Business Combination that may be required, or considered appropriate, as a result of applicable laws or regulations; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement; (vi) the ability to complete the contemplated PIPE investment, the senior secured term loan, the committed equity facility and the RTW Investments synthetic royalty financing in connection with the Business Combination; (vii) Pubco’s ability to acquire sufficient sources of funding if and when needed; (viii) the effect of the announcement or pendency of the Business Combination on Allurion’s business relationships, operating results and business generally; (ix) risks that the Business Combination disrupts current plans and operations of Allurion; (x) the ability of Pubco to implement business plans, forecasts and other expectations after the completion of the Business Combination, and identify and realize additional opportunities; (xi) significant risks, assumptions, estimates and uncertainties related to the projected financial information with respect to Allurion; (xii) the outcome of any legal proceedings that may be instituted against Allurion, Pubco or Compute Health following the announcement of the business combination agreement or the Business Combination; (xiii) Allurion’s ability to commercialize current and future products and services and create sufficient demand among health care providers and patients; (xiv) Allurion’s ability to successfully complete current and future preclinical studies and clinical trials of the Allurion Balloon and any other future product candidates; (xv) Allurion’s ability to obtain market acceptance of the Allurion Balloon as safe and effective; (xvi) Allurion’s ability to cost-effectively sell existing and future products through existing distribution arrangements with distributors and/or successfully adopt a direct sales force as part of a hybrid sales model that includes both distributors and a direct sales effort; (xvii) Allurion’s ability to obtain regulatory approval or clearance in the U.S. and certain non-U.S. jurisdictions for current and future products and maintain previously obtained approvals and/or clearances in those jurisdictions where Allurion’s products and services are currently offered; (xviii) Allurion’s ability to accurately forecast customer demand and manufacture sufficient quantities of product that patients and health care providers request; (xix) Allurion’s ability to successfully compete in the highly competitive and rapidly changing regulated industries in which Allurion operates, and effectively address changes in such industries, including changes in competitors’ products and services and changes in the laws and regulations that affect Allurion; (xx) Allurion’s ability to successfully manage future growth and any future international expansion of Allurion’s business and navigate the risks associated with doing business internationally; (xxi) Allurion’s ability to obtain and maintain intellectual property protection for its products and technologies and acquire or license intellectual property from third parties; (xxii) the ability of Pubco to retain key executives; (xxiii) the ability to obtain and maintain the listing of Pubco’s securities on a national securities exchange; (xxiv) Allurion’s ability to properly train physicians in the use of the Allurion Gastric Balloon and other services it offers in its practices; (xxv) the risk of downturns in the market and Allurion’s industry including, but not limited to, as a result of the COVID-19 pandemic; (xxvi) fees, costs and expenses related to the Business Combination; (xxvii) the risk that the parties to the Medtronic collaboration agreement will not achieve the expected benefits, incremental revenue and opportunities from such arrangement; (xxviii) the failure to realize anticipated benefits of the Business Combination or to realize estimated pro forma results and underlying assumptions, including with respect to estimated redemptions by Compute Health’s public stockholders; and (xxix) sanctions against Russia, reductions in consumer confidence, heightened inflation, production disruptions in Europe, cyber disruptions or attacks, higher natural gas costs, higher manufacturing costs and higher supply chain costs. The foregoing list of factors is not exclusive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Compute Health’s Annual Report on Form 10-K for the year ended December 31, 2022 and the proxy statement/prospectus contained in the Registration Statement (333-271862), and other documents filed by Compute Health and Pubco from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and none of Allurion, Pubco or Compute Health assume any obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. None of Compute Health, Allurion or Pubco gives any assurance that Compute Health or Allurion, or Pubco, will achieve its expectations.

Non-solicitation

This press release and the information contained herein is not a proxy statement/prospectus or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential business combination or any other matter and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Compute Health, Allurion, or Pubco, or a solicitation of any vote or approval, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Contacts

Media Contact
Erik Milster
emilster@seriesmpr.com

Investor Contact
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com

ATLANTA–(BUSINESS WIRE)–Loyal, the preferred digital health platform for improved care utilization by the nation’s leading health systems and hospitals, announced today it has named Austin Pauls as Loyal’s first Chief Financial Officer. In this role, Pauls will work cross-functionally to identify and fulfill opportunities for continued growth and operational excellence.

“I’m excited to add Austin’s leadership and experience to our finance and executive teams at this important time for our company,” said Loyal CEO Chad Mallory. “His experience working with high-growth companies as they build toward both fundraising and profitability goals will be especially helpful in the months and years ahead.”

Pauls brings 17 years of financial leadership experience to Loyal’s team, and he most recently served as vice president of Finance for Atlanta-based Stord, a supply chain software and services company. In this role, Pauls led the finance and accounting teams and helped raise over $300 million in funding. Prior to Stord, Pauls served in finance leadership roles at both WeWork and Borderfree, and earlier in his career held roles with RBC Capital Markets and KPMG.

“I’m delighted to join the team at Loyal in its mission to improve the care experience for both patients and providers,” said Pauls. “The company has a strong foundation on which it can grow, and I believe there are meaningful opportunities for value creation ahead as the company continues to scale.”

Pauls holds a Bachelor of Business Administration in Accounting from the University of Notre Dame.

To learn more about Loyal’s full range of solutions to improve the healthcare consumer experience, visit loyalhealth.com.

About Loyal

Loyal is a healthcare consumer experience company solely dedicated to the betterment of patient care. As the preferred platform for improved care utilization used by the nation’s leading health systems and hospitals, Loyal’s AI-powered solution makes it easier for patients to connect and access care across their entire health journey, thereby driving loyalty with their trusted health provider. Streamline patients’ navigation of your health system and network of clinical services with LoyalHealth.com.

Contacts

Media
Maggie Vautrinot
PAN Communications for Loyal
LoyalHealth@pancomm.com

ATLANTA–(BUSINESS WIRE)–Loyal, the preferred digital health platform for improved care utilization by the nation’s leading health systems and hospitals, announced today that Matt Gove has joined the company as Senior Advisor.

For more than a decade, Gove has been one of the healthcare industry’s most recognized and respected advocates for consumer-centric marketing and digital experiences, leading those functions and more for Piedmont Healthcare and Summit Health/CityMD. At Loyal, Gove will work directly with CEO Chad Mallory to provide strategic counsel as the company continues to expand its platform and become the partner of choice for forward-thinking, consumer-centric healthcare organizations.

“Matt has a unique skill set and has done as much as anyone to push the healthcare industry to elevate the consumer digital experience. We are thrilled to have him join our team,” said Mallory. “Over the past few years, Loyal has grown from a best-in-class provider of point solutions to a true platform company. Matt will help us share that story more effectively and build on that success.”

With more than 25 years of marketing, communications and consumer strategy experience, Gove served most recently as chief marketing officer for NYC-based Summit Health/CityMD, which was acquired by VillageMD in January. Previously, he served as chief consumer officer for Piedmont Healthcare, where he was responsible for marketing, consumer experience, communications, community benefits and government relations for Georgia’s largest health system. Under Gove’s leadership, the Piedmont team established a reputation as a national leader in consumer-centric marketing and digital experience design.

“It has been a thrill to see healthcare companies finally embrace their customers and offer digital tools that meet patients where they are. The next step for those companies is to find a solution that not only makes it easier for patients but delivers a consolidated platform that actually improves operations as well,” added Gove. “Loyal is the only platform that can do that and I’m incredibly excited to be joining at this point in its growth.”

To learn more about Loyal and its full range of solutions to improve the healthcare consumer experience, visit loyalhealth.com.

About Loyal

Loyal is a healthcare consumer experience company solely dedicated to the betterment of patient care. As the preferred platform for improved care utilization used by the nation’s leading health systems and hospitals, Loyal’s AI-powered solution makes it easier for patients to connect and access care across their entire health journey, thereby driving loyalty with their trusted health provider. Streamline patients’ navigation of your health system and network of clinical services with LoyalHealth.com.

Contacts

Media
Maggie Vautrinot
PAN Communications for Loyal
LoyalHealth@pancomm.com

Kandu Health achieves successful enrollment of the first 50 stroke survivors in its stroke recovery program

CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company elevating care for people affected by stroke and other ischemic diseases, today announced the appointment of Kirsten Carroll as Chief Executive Officer of Kandu Health, Inc., a digital health startup company with the aim of improving quality of life for people affected by stroke. The company also announced the successful enrollment of the first 50 stroke survivors in its program and the appointments of Chief Financial Officer Stefan Heuser and Senior Vice President of Commercialization, Clayton Duncan.

Appointment of Kirsten Carroll as Chief Executive Officer of Kandu Health

“The patient is the one constant in the continuum of care for stroke. Our vision for Imperative Care has always been to connect each part of the care journey for patients affected by stroke and be the company that delivers both treatment and post-acute care for stroke survivors,” said Fred Khosravi, Chairman and CEO for Imperative Care. “Kirsten has championed this vision for Kandu Health since its early days. Through her leadership and the company’s impressive bench of leaders, I see the embodiment of our mission to provide real, life-changing care to stroke survivors.”

Carroll previously served as Senior Vice President and General Manager for Kandu Health, leading the company from inception through its formation as an independent company. She brings more than 20 years of experience in stroke product development, clinical research, marketing, strategy and business development. Carroll holds an MBA and a Masters of Public Health from Haas School of Business at University of California, Berkeley, and a Bachelor’s of Science in biomedical engineering from Yale University.

“Once a person has a stroke, every aspect of their life can be affected, diminishing both their quality of life and health. Improving these outcomes for stroke survivors has been my passion for over 20 years now, and Kandu is the most important thing I have worked on in that time,” said Carroll. “The Kandu program is intended to address critical gaps in care and to provide personalized support to stroke survivors as they transition back home from the hospital. It is my greatest privilege to step into this new role and lead the company forward in delivering on our mission.”

In the U.S., approximately eight million people are living with the effects of stroke.¹ Historically, most investment in stroke care has focused on acute intervention. Kandu Health delivers tech-enabled healthcare services, providing remote support to stroke survivors and care partners after hospital discharge.

Successful Enrollment of the First 50 Stroke Survivors

Kandu Health is working to fulfill an urgent need in healthcare by supporting stroke patients beyond the hospital through a team of clinically licensed navigators, community support groups, and an easy-to-use app. With goals to reduce hospital stays and readmissions, lower the cost of healthcare, and improve patient satisfaction, Kandu Health works closely with healthcare institutions to ensure that care is well integrated and coordinated with existing programming. This also provides hospital staff with assurance that their patients are safe and connected to the best resources. Kandu Health began piloting its program with its first hospital partners in the greater Los Angeles and South New Jersey areas. More than 50 stroke survivors have enrolled in the program and early data have shown enrollment rates, engagement and outcomes that exceed expectations for the program.

Appointment of Stefan Heuser as Chief Financial Officer of Kandu Health

Stefan Heuser brings decades of executive leadership experience in finance to Kandu Health. He previously served as Vice President and Head of Investments at Hyundai Motor Group’s Corporate Venture Capital Arm. Prior to joining Hyundai, he was the Vice President of Operations and Innovation at Samsung Strategy and Innovation Center with global operational responsibility for programs in Digital Health, Internet of Things, and Autonomous Driving. He also has experience building and leading an early-stage venture investment team for Samsung Global Innovation Center and serving as the CFO and VP of Finance for Siemens Smart Grid Applications. Heuser holds an MBA from Ludwig-Maximilian University of Munich.

Appointment of Clayton Duncan as SVP, Commercialization of Kandu Health

Clayton Duncan has over 20 years of leadership experience in strategic growth roles within early and growth-stage healthcare companies. With broad experience leading value-based and integrated care solutions initiatives, he leads Kandu’s commercialization efforts focused on creating accretive strategic partnerships with payers, providers, and other healthcare enterprises. Duncan holds a Masters degree from Thunderbird School of Global Management at Arizona State University, a JD from Southern Methodist University’s Dedman School of Law, and a Bachelor’s degree in finance from Texas Tech University.

“We have seen very promising results in data collected from some of the first 50 stroke survivors enrolled in our program, and these survivors have uniformly endorsed the program, noting that it has strengthened their health, agency and quality of life. I am excited to continue scaling our program to have an impact on many more stroke survivors and their families,” Duncan said.

About Kandu Health, Inc.

Kandu Health provides tech-enabled healthcare services to people recovering from stroke. Kandu Health develops integrated solutions that aid in the stroke recovery process for stroke survivors, their providers, and care partners. Kandu Health is based in Campbell, CA. https://kanduhealth.com.

About Imperative Care, Inc.

Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company has four businesses focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com.

1. Cerebrovascular Disease or Stroke. Centers for Disease Control. 2023. https://www.cdc.gov/nchs/fastats/stroke.htm

Contacts

Investor Contact
Matthew Garrett, CFO, Imperative Care, Inc.
mgarrett@imperativecare.com

Media Contact
Jana Chow, Director of Communications
jchow@imperativecare.com